Annovis Bio Announces Filing of Patent Covering the Administration of Buntanetap and Its Analogues for the Treatment of Mental Illnesses

See more here


Strados Labs Forms Collaboration with Boehringer Ingelheim for its Idiopathic Pulmonary Fibrosis (IPF) Pilot Study

Starting in early 2023 the biopharmaceutical company will use the Strados RESP™ Biosensor to remotely monitor cough and crackles in patients at home.

See more here


Annovis Bio Announces Patient Enrollment Update For Phase 3 Study of Buntanetap for the Treatment of Parkinson’s Disease

Strong enrollment in Phase 3 trial demonstrates continued execution

Interim analysis expected in 2Q 2023

See more here


iVIEW announces Completion of First Patient Treatment in Phase II Clinical Study of IVIEW-1201 for the Treatment of Bacterial Conjunctivitis

See more here


Relmada Therapeutics Appoints Fabiana Fedeli from M&G Investments to its Board of Directors

See more here


Scipher Medicine Acquires CrossBridge and its SaaS Platform to Collect and Map Patient Molecular, Outcomes and Claims Data in Real Time

First-of-its-kind technology stack in autoimmune diseases.

Provides unprecedented insights into optimal patient treatment pathway.

See more here


Relmada Therapeutics Appoints CNS Therapeutic Expert Cedric O’Gorman MD as Chief Medical Officer

See more here


AbbVie and Immunome Announce Strategic Collaboration to Discover Multiple Novel Oncology Targets

– Multi-year collaboration to identify up to 10 novel target-antibody pairs leveraging Immunome’s Discovery Engine

– Immunome to receive $30M upfront payment with potential for further platform access and option payments as well as development, commercial, and sales-based milestones, and tiered royalties

See more here


Annovis Bio Announces New Appointments to Strengthen Its Senior Leadership Team

See more here


Palvella Therapeutics Announces Series D Financing of Up to $37.7 Million to Accelerate Late-Stage Development and Support Commercialization of Novel Therapies for Serious, Rare Genetic Skin Diseases

Led by new investor Petrichor, with participation from new and existing investors

Lead product candidate, QTORIN™ rapamycin, in late-stage clinical development for serious, rare genetic skin diseases with no FDA-approved therapies

Top-line data expected in mid-2023 from Phase 3 pivotal study evaluating QTORIN™ rapamycin in Pachyonychia Congenita

See more here